We are live on ! Find out more
MLTX icon

MoonLake Immunotherapeutics
MLTX

125 hedge funds and large institutions have $3.53B invested in MoonLake Immunotherapeutics in 2023 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 51 increasing their positions, 33 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 33

32% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 28

10% more capital invested

Capital invested by funds: $3.21B → $3.53B (+$322M)

6% more funds holding

Funds holding: 118 → 125 (+7)

6.21% less ownership

Funds ownership: 105.3% → 99.09% (-6.2%)

16% less call options, than puts

Call options by funds: $39.7M | Put options by funds: $47.3M

40% less funds holding in top 10

Funds holding in top 10: 10 → 6 (-4)

Holders
125
Holders Change
+7
Holders Change %
+5.93%
% of All Funds
1.82%
Holding in Top 10
6
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-40%
% of All Funds
0.09%
New
37
Increased
51
Reduced
33
Closed
28
Calls
$39.7M
Puts
$47.3M
Net Calls
-$7.57M
Net Calls Change
+$48.7M

Top Buyers

Rank Fund Capital Flow
1
DGM
Darwin Global Management
Jersey
+$53.6M
2
Holocene Advisors
Holocene Advisors
New York
+$44.1M
3
ACA
Avoro Capital Advisors
New York
+$29.9M
4
FC
Finepoint Capital
Massachusetts
+$29M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$23.2M

Top Sellers

Rank Fund Capital Flow
1
APM
Avidity Partners Management
Texas
-$44.3M
2
RI
RTW Investments
New York
-$28.5M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$22M
4
BlackRock
BlackRock
New York
-$18.9M
5
IHAM
Integral Health Asset Management
New York
-$14.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
Susquehanna International Group
26
Susquehanna International Group
Pennsylvania
$12.9M +$10.2M +196,964 +1,148%
TD Asset Management
27
TD Asset Management
Ontario, Canada
$12.6M +$451K +8,752 +4%
N
28
Nuveen
North Carolina
$11.9M +$2.9M +56,315 +40%
CS
29
Candriam SCA
Luxembourg
$11.2M +$9.53M +185,000 New
SC
30
Stempoint Capital
New York
$10.1M +$8.65M +167,851 New
SSA
31
Schonfeld Strategic Advisors
New York
$9.69M -$9.29M -180,300 -53%
Lord, Abbett & Co
32
Lord, Abbett & Co
New Jersey
$9.62M -$862K -16,718 -9%
SIG
33
Senator Investment Group
New York
$9.36M +$7.99M +155,000 New
Victory Capital Management
34
Victory Capital Management
Texas
$9.34M -$1.46M -28,370 -16%
Goldman Sachs
35
Goldman Sachs
New York
$9.13M +$2.81M +54,447 +56%
LGM
36
Logos Global Management
California
$9.06M +$7.73M +150,000 New
ABG
37
Ally Bridge Group
New York
$8.66M -$2.04M -39,626 -22%
Morgan Stanley
38
Morgan Stanley
New York
$8.03M +$6.37M +123,577 +1,308%
D.E. Shaw & Co
39
D.E. Shaw & Co
New York
$7.77M +$6.63M +128,700 New
GIM
40
Granahan Investment Management
Massachusetts
$7.66M +$2.18M +42,210 +50%
WP
41
Woodline Partners
California
$7.35M +$1.03M +20,005 +20%
SI
42
Sofinnova Investments
California
$6.87M -$9.23M -179,048 -61%
Axa
43
Axa
France
$6.29M -$988K -19,165 -16%
SFM
44
Soros Fund Management
New York
$6.04M +$2.27M +44,000 +79%
Manulife (Manufacturers Life Insurance)
45
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$5.07M +$526K +10,210 +14%
PA
46
Perceptive Advisors
New York
$4.98M +$4.25M +82,398 New
PHP
47
Parkman Healthcare Partners
Connecticut
$4.95M +$1.48M +28,716 +54%
GTC
48
Ghost Tree Capital
New York
$4.83M -$12.9M -250,000 -76%
Jane Street
49
Jane Street
New York
$4.71M +$3.76M +72,958 +1,462%
CM
50
Caption Management
Oklahoma
$4.53M +$3.5M +67,957 +965%
1
2
3 4 5

MLTX Hedge Fund Activity: Q4 2023 in Review

125 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q4 2023, worth a combined $3.53B — up 10% from $3.21B a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new MLTX positions and 28 closed out — a net gain of 9 holders — while 51 added to existing stakes and 33 trimmed.

The largest buyer was Darwin Global Management, opening a new position worth an estimated $53.6M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $44.3M sold.

  • 125 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q4 2023, up from 118 in Q3 2023.
  • Funds reported $3.53B of MoonLake Immunotherapeutics stock for Q4 2023, up 10% quarter-over-quarter.
  • 37 funds opened new MoonLake Immunotherapeutics positions in Q4 2023 and 28 closed out, a net change of +9 holders.
  • The largest MoonLake Immunotherapeutics buyer in Q4 2023 was Darwin Global Management, an estimated $53.6M added.
  • The largest MoonLake Immunotherapeutics seller in Q4 2023 was Avidity Partners Management, an estimated $44.3M sold.

Based on aggregated 13F filings for Q4 2023.